Last reviewed · How we verify
NCT05204355
MRI for Screening and Monitoring Scleroderma ILD
trial testing MRI in Scleroderma in 25 participants. Participants enrolled and being followed up; not accepting new ones.
31 March 2025
Quick facts
| Lead sponsor | University of Kansas Medical Center |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 25 |
| Start date | 1 May 2022 |
| Primary completion | 31 March 2025 |
| Estimated completion | 31 October 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- MRI — full drug profile →
- Hyperpolarized Xe129 — full drug profile →
- HRCT
Conditions studied
- Scleroderma — all drugs for Scleroderma →
Sponsor
University of Kansas Medical Center
Who can join
18 and older, any sex, with Scleroderma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to test MRI methods for evaluating patients with Scleroderma-associated interstitial lung disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05204355
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of MRI
Trials testing the same drug.
- NCT02831335 — Technical Development of Multi-Parametric Renocerebral MRI · recruiting
- NCT07487870 — Radiographic Evaluation of Tumor Biology During Neoadjuvant Radiotherapy for Sarcoma · NA · not yet recruiting
- NCT07567053 — Repetitive Transcranial Magnetic Stimulation on Motor Function and Meta-Plasticity in Cerebral Palsy: TMS-EEG Study · NA · not yet recruiting
- NCT07537504 — Language Function Reorganization in Patients With Arteriovenous Malformations · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Scleroderma
Currently open trials in the same condition.
- NCT07292961 — Investigating the Effectiveness of the Biopsychosocial Model-Based Exercise Approach in Children and Adults Diagnosed Wi · NA · recruiting
- NCT06801119 — Efficacy and Safety of HN2301 in Autoimmune Diseases（AIDs） · Phase 1 · recruiting
- NCT06554132 — Respiratory Muscle Strength and Aerobic Capacity in Scleroderma · recruiting
- NCT03800017 — Skeletal Muscle Function in Interstitial Lung Disease · NA · recruiting
- NCT06598982 — Investigation of Respiratory Muscle Sarcopenia in Patients With Systemic Sclerosis · recruiting
Other University of Kansas Medical Center trials
Trials by the same sponsor.
- NCT06636214 — Adapting Changing Talk: Online (CHATO) to CHATO-Inclusive · NA · not yet recruiting
- NCT07528963 — KanSurvive 2.0: Testing Enhanced Models of Cancer Survivorship Care for Rural Cancer Survivors in Primary Care Practice · NA · enrolling by invitation
- NCT07463755 — Low-Fidelity Driving Simulator Training in Parkinson's Disease. · NA · not yet recruiting
- NCT07420621 — Preliminary Effectiveness of Enhanced Text Message + Incentives · NA · recruiting
- NCT07491510 — Improving Prenatal Care to Reduce Early Onset Preeclampsia in Low-Income · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05204355 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Kansas Medical Center
- Last refreshed: 2 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05204355.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing